EA202091429A1 - Замещенные амиды i пирролидина - Google Patents

Замещенные амиды i пирролидина

Info

Publication number
EA202091429A1
EA202091429A1 EA202091429A EA202091429A EA202091429A1 EA 202091429 A1 EA202091429 A1 EA 202091429A1 EA 202091429 A EA202091429 A EA 202091429A EA 202091429 A EA202091429 A EA 202091429A EA 202091429 A1 EA202091429 A1 EA 202091429A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrrolidine
substituted amides
glucocorticoid receptor
modulators
diseases
Prior art date
Application number
EA202091429A
Other languages
English (en)
Inventor
Флориан Якоб
Йо Ален
Зебастиан Крюгер
Маркус Шаде
Даниэла Фрибе
Штефани Хеннен
Original Assignee
Грюненталь Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Грюненталь Гмбх filed Critical Грюненталь Гмбх
Publication of EA202091429A1 publication Critical patent/EA202091429A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение относится к соединениям, соответствующим общей формуле (I)которые действуют как модуляторы глюкокортикоидного рецептора и могут быть применены для лечения и/или профилактики заболеваний, которые, по меньшей мере, частично опосредованы глюкокортикоидным рецептором.
EA202091429A 2017-12-18 2018-12-18 Замещенные амиды i пирролидина EA202091429A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17208175 2017-12-18
PCT/EP2018/085383 WO2019121606A1 (en) 2017-12-18 2018-12-18 Substituted pyrrolidine amides i

Publications (1)

Publication Number Publication Date
EA202091429A1 true EA202091429A1 (ru) 2020-10-27

Family

ID=60673845

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091429A EA202091429A1 (ru) 2017-12-18 2018-12-18 Замещенные амиды i пирролидина

Country Status (14)

Country Link
US (1) US10626106B2 (ru)
EP (1) EP3728219B1 (ru)
JP (1) JP2021506964A (ru)
CN (1) CN111556867A (ru)
AR (1) AR113967A1 (ru)
AU (1) AU2018387793A1 (ru)
BR (1) BR112020012217A2 (ru)
CA (1) CA3085874A1 (ru)
EA (1) EA202091429A1 (ru)
ES (1) ES2925198T3 (ru)
IL (1) IL275374A (ru)
MX (1) MX2020006348A (ru)
TW (1) TW201927770A (ru)
WO (1) WO2019121606A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020207591A1 (en) * 2019-01-11 2021-09-02 Grünenthal GmbH Substituted pyrrolidine amidesIII
WO2022008705A1 (en) 2020-07-09 2022-01-13 Grünenthal GmbH Substituted pyrrolidine amines and amides as mediator of the glucocortoid receptor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7388953B2 (en) 1999-09-24 2008-06-17 Verizon Business Global Llc Method and system for providing intelligent network control services in IP telephony
ES2414479T3 (es) * 2005-04-14 2013-07-19 Glaxo Group Limited Indazoles como ligandos del receptor de glucocorticoides
BRPI0710240A2 (pt) * 2006-04-20 2011-08-09 Glaxo Group Ltd composto, uso de um composto, método para o tratamento de um paciente humano ou animal com uma condição ou doença, composição farmacêutica, combinação, e, processo para a preparação de um composto
GB0620385D0 (en) 2006-10-13 2006-11-22 Glaxo Group Ltd Novel compounds
TW200829578A (en) * 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
WO2009035067A1 (ja) 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. １，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体からなるグルココルチコイド受容体アゴニスト
US20100080786A1 (en) * 2008-05-20 2010-04-01 Markus Berger Phenyl or Pyridinyl Substituted Indazoles Derivatives
WO2015099196A1 (en) * 2013-12-26 2015-07-02 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
WO2016046260A1 (en) 2014-09-26 2016-03-31 Astrazeneca 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators
CA2996278A1 (en) 2015-08-25 2017-03-02 Santen Pharmaceutical Co., Ltd. [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1h-quinoxalin-7-yl)-phenoxy]ethyloxy compound or salt thereof
TW201927769A (zh) 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ｉｉ

Also Published As

Publication number Publication date
ES2925198T3 (es) 2022-10-14
AU2018387793A1 (en) 2020-07-30
US10626106B2 (en) 2020-04-21
AR113967A1 (es) 2020-07-01
MX2020006348A (es) 2020-09-03
CN111556867A (zh) 2020-08-18
US20190185455A1 (en) 2019-06-20
EP3728219A1 (en) 2020-10-28
IL275374A (en) 2020-07-30
BR112020012217A2 (pt) 2020-11-24
JP2021506964A (ja) 2021-02-22
CA3085874A1 (en) 2019-06-27
WO2019121606A1 (en) 2019-06-27
EP3728219B1 (en) 2022-04-13
TW201927770A (zh) 2019-07-16

Similar Documents

Publication Publication Date Title
EA202091428A1 (ru) Замещенные амиды ii пирролидина
EA201790806A1 (ru) Иммунорегулирующие средства
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
GEP20207147B (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
EA201792231A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
EA201991598A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR)
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201991599A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR)
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
EA201891336A1 (ru) Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
EA201890256A1 (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
MX2021008364A (es) Amidas de pirrolidina iii sustituidas.
EA201692037A1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
MX2017015741A (es) Moduladores de ror gamma (ror?).
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
MX2017015740A (es) Moduladores de ror gamma (ror?).
EA201790570A1 (ru) Модуляторы р2х7
EA201691544A1 (ru) Твердые формы 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида, его композиции и способы его применения
PH12016501613B1 (en) Pyrazines modulators of gpr6